Qianxi Chen

Qianxi Chen


Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 January 2026 in Scientific Reports
Verified
Journal Article
Open access
PDF file
XCXiaoping Chen
Xiaoping Chen
KCKehan Chen
Kehan Chen
XMXingxing Ma
Xingxing Ma
BCBo Chen
Bo Chen
PLPeng Liang
Peng Liang
QCQianxi Chen
Qianxi Chen
Background Lung cancer remains the deadliest malignancy globally. Although therapies, including immune checkpoint inhibitors and targeted therapy, have gradually prolonged overall survival, resistance and relapse still plague clinical management. Baicalein, a naturally derived compound exhibiting potent antitumor and anti-inflammatory properties, is widely regarded as a promising candidate for the development of anticancer therapeutic agents. Nevertheless, its mechanism of action in lung cancer remains unclear. Objective This study aims to elucidate the multi-target pharmacological mechanism by which Baicalein acts in lung cancer treatment, utilizing network pharmacology, immune infiltration analysis, molecular docking, and molecular dynamics simulation. Methods Using the TCMSP, Swiss Target Prediction, and Pharm Mapper databases, we identified the relevant targets of Baicalein. Meanwhile, lung cancer-associated targets were retrieved from the GeneCards database. The targets were obtained by taking the intersection of these two sets. A protein-protein interaction (PPI) network was then constructed using Cytoscape. Furthermore, the influence of these core targets to the tumor immune microenvironment was investigated via immune infiltration analysis. Finally, we employed molecular docking to evaluate the binding affinity between Baicalein and targets, followed by molecular dynamics simulations to confirm the stability of these interactions. Results A total of 92 potential targets of Baicalein for lung cancer were identified. Five core targets, including TP53, AKT1, MAPK3, BCL2, and EGFR, were determined based on the connectivity characteristics of the PPI network. These core targets were significantly enriched in the PI3K-AKT signaling pathway. Molecular dynamics simulations displayed that the binding free energy of the AKT1–baicalein complex was − 199.8 kJ/mol. Energy decomposition analysis suggested that complex stabilization is primarily driven by shape complementarity and hydrophobic effects, rather than conventional hydrogen bonding or salt bridges. Conclusion This study reveals that the antitumor activity of Baicalein is mediated through its multi-target action on core components of the PI3K-AKT pathway, thereby offering novel insights for exploring its therapeutic targets.

2 February 2026 in PLOS ONE
Verified
Journal Article
Open access
SLShaohuan Lu
Shaohuan Lu
DWDongxiao Wang
Dongxiao Wang
CXCaiming Xiong
Caiming Xiong
JLJialing Liang
Jialing Liang
YLYang Li
Yang Li
GMGuangyi Meng
Guangyi Meng
Objective: To detect and quantify adverse drug event (ADE) signals linked to 120 mg denosumab in the real world. Methods: We queried the US Food and Drug Administration Adverse Event Reporting System (FAERS) for reports on 120 mg denosumab, standardized, and categorized these events with Preferred Terms (PT) and System Organ Classes (SOC) from MedDRA version 27.1. Disproportionality analysis was performed using the reporting odds ratio (ROR) and Bayesian confidence propagation neural network (BCPNN). Results: We identified 10,963 ADE reports for 120 mg of denosumab. Among 10 963 reports, 41.6% of patients were ≥ 65 years old, 37.1% were from the United States, and 17.7% were from Japan; 77.0% were serious. Data mining revealed 294 positive disproportionality signals across 27 SOCs. The highest signal proportions were for neoplasms (15.99%), musculoskeletal disorders (13.27%), infections (11.56%), gastrointestinal disorders (10.88%), and procedural complications (10.20%). The most frequent ADEs were osteonecrosis of the jaw (n = 3,082, 28.11%), death (n = 803, 7.32%), hypocalcemia (n = 799, 7.29%), and fatigue (n = 282, 2.57%). The strongest signals by ROR were bone giant cell tumor (7888.08), bone giant cell tumor malignant (6502.96), osteonecrosis of the jaw (396.57), and bone giant cell tumor benign (312.37). Thirty-two unlisted events were identified, including exostosis of jaw, osteosarcoma, tooth fracture, and bone lesions. Conclusions: Clinicians should maintain vigilance for both established toxicities and these 32 emerging signals to ensure the safety of patients receiving 120 mg of denosumab for oncological purposes.